Literature DB >> 33197449

Plasmid Acquisition Alters Vancomycin Susceptibility in Clostridioides difficile.

Meng Pu1, Janice M Cho1, Scott A Cunningham2, Gaurav K Behera1, Sarah Becker1, Talal Amjad1, Kerryl E Greenwood-Quaintance2, Helena Mendes-Soares3, Yava Jones-Hall4, Patricio R Jeraldo3, Jun Chen5, Gary Dunny6, Robin Patel7, Purna C Kashyap8.   

Abstract

The increasing incidence of primary and recurring Clostridioides difficile infections (CDI), which evade current treatment strategies, reflects the changing biology of C difficile. Here, we describe a putative plasmid-mediated mechanism potentially driving decreased sensitivity of C difficile to vancomycin treatment. We identified a broad host range transferable plasmid in a C difficile strain associated with lack of adequate response to vancomycin treatment. The transfer of this plasmid to a vancomycin-susceptible C difficile isolate decreased its susceptibility to vancomycin in vitro and resulted in more severe disease in a humanized mouse model. Our findings suggest plasmid acquisition in the gastrointestinal tract to be a possible mechanism underlying vancomycin treatment failure in patients with CDI, but further work is needed to characterize the mechanism by which plasmid genes determine vancomycin susceptibility in C difficile.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amidase; Antimicrobial Resistance; Cell Wall Peptidoglycan; Gram Positive

Year:  2020        PMID: 33197449      PMCID: PMC7878333          DOI: 10.1053/j.gastro.2020.10.046

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  10 in total

1.  Clinical and molecular characteristics of an outbreak caused by the pandemic (BI/NAP1/027) Clostridium difficile clone in a single center in Israel.

Authors:  Yonit Wiener-Well; Eli Ben-Chetrit; Mustafa Abed-Eldaim; Marc V Assous; Tamar Miller-Roll; Amos Adler
Journal:  Infect Control Hosp Epidemiol       Date:  2014-09-02       Impact factor: 3.254

2.  A national survey of the molecular epidemiology of Clostridium difficile in Israel: the dissemination of the ribotype 027 strain with reduced susceptibility to vancomycin and metronidazole.

Authors:  Amos Adler; Tamar Miller-Roll; Rita Bradenstein; Colin Block; Bracha Mendelson; Miriam Parizade; Yossi Paitan; David Schwartz; Nehama Peled; Yehuda Carmeli; Mitchell J Schwaber
Journal:  Diagn Microbiol Infect Dis       Date:  2015-06-03       Impact factor: 2.803

3.  Increasing antibiotic resistance in Clostridioides difficile: A systematic review and meta-analysis.

Authors:  Srishti Saha; Saloni Kapoor; Raseen Tariq; Audrey N Schuetz; Pritish K Tosh; Darrell S Pardi; Sahil Khanna
Journal:  Anaerobe       Date:  2019-07-19       Impact factor: 3.331

4.  Antimicrobial susceptibility of Clostridium difficile isolates in Israel.

Authors:  Linda Tkhawkho; Orna Nitzan; Nina Pastukh; Diana Brodsky; Karen Jackson; Avi Peretz
Journal:  J Glob Antimicrob Resist       Date:  2017-07-17       Impact factor: 4.035

5.  Clostridioides difficile Whole-genome Sequencing Differentiates Relapse With the Same Strain From Reinfection With a New Strain.

Authors:  Janice Cho; Scott Cunningham; Meng Pu; Ryan J Lennon; Jennifer Dens Higano; Patricio Jeraldo; Priya Sampathkumar; Samantha Shannon; Purna C Kashyap; Robin Patel
Journal:  Clin Infect Dis       Date:  2021-03-01       Impact factor: 9.079

6.  Clostridioides difficile uses amino acids associated with gut microbial dysbiosis in a subset of patients with diarrhea.

Authors:  Eric J Battaglioli; Vanessa L Hale; Jun Chen; Patricio Jeraldo; Coral Ruiz-Mojica; Bradley A Schmidt; Vayu M Rekdal; Lisa M Till; Lutfi Huq; Samuel A Smits; William J Moor; Yava Jones-Hall; Thomas Smyrk; Sahil Khanna; Darrell S Pardi; Madhusudan Grover; Robin Patel; Nicholas Chia; Heidi Nelson; Justin L Sonnenburg; Gianrico Farrugia; Purna C Kashyap
Journal:  Sci Transl Med       Date:  2018-10-24       Impact factor: 17.956

7.  Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection.

Authors:  Milagros Gonzales; Jacques Pepin; Eric H Frost; Julie C Carrier; Stephanie Sirard; Louis-Charles Fortier; Louis Valiquette
Journal:  BMC Infect Dis       Date:  2010-12-30       Impact factor: 3.090

8.  Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease.

Authors:  Sahil Khanna; Yoshiki Vazquez-Baeza; Antonio González; Sophie Weiss; Bradley Schmidt; David A Muñiz-Pedrogo; John F Rainey; Patricia Kammer; Heidi Nelson; Michael Sadowsky; Alexander Khoruts; Stefan L Farrugia; Rob Knight; Darrell S Pardi; Purna C Kashyap
Journal:  Microbiome       Date:  2017-05-15       Impact factor: 14.650

9.  Plasmid-mediated metronidazole resistance in Clostridioides difficile.

Authors:  Ilse M Boekhoud; Bastian V H Hornung; Eloisa Sevilla; Céline Harmanus; Ingrid M J G Bos-Sanders; Elisabeth M Terveer; Rosa Bolea; Jeroen Corver; Ed J Kuijper; Wiep Klaas Smits
Journal:  Nat Commun       Date:  2020-01-30       Impact factor: 14.919

10.  Antimicrobial susceptibility of Brazilian Clostridium difficile strains determined by agar dilution and disk diffusion.

Authors:  Edmir Geraldo Fraga; Antonio Carlos Nicodemo; Jorge Luiz Mello Sampaio
Journal:  Braz J Infect Dis       Date:  2016-08-16       Impact factor: 3.257

  10 in total
  3 in total

Review 1.  Mechanisms and impact of antimicrobial resistance in Clostridioides difficile.

Authors:  Chetna Dureja; Abiola O Olaitan; Julian G Hurdle
Journal:  Curr Opin Microbiol       Date:  2022-01-22       Impact factor: 7.584

Review 2.  Antimicrobial resistance in Clostridioides difficile.

Authors:  Keeley O'Grady; Daniel R Knight; Thomas V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-08-24       Impact factor: 3.267

Review 3.  Genetic Mechanisms of Vancomycin Resistance in Clostridioides difficile: A Systematic Review.

Authors:  Taryn A Eubank; Anne J Gonzales-Luna; Julian G Hurdle; Kevin W Garey
Journal:  Antibiotics (Basel)       Date:  2022-02-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.